Novel Therapeutic Target(s) for Psoriatic Disease

Vishal Thakur and Rahul Mahajan*

Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Psoriasis and psoriatic arthritis, together known as psoriatic disease, is highly prevalent chronic relapsing inflammatory disease affecting skin, joints or both and is associated with several comorbidities such as cardiovascular, metabolic, psychiatric, renal disease etc. The etiopathogenesis of psoriasis is complex and mainly driven by aberrant immune response owing to the genetic susceptibility and various environmental factors such as trauma, infections and drugs. Recent advances in understanding molecular and cellular pathways have identified tumor necrosis factor-α (TNF-α), interleukin-17 (IL-17), IL-23, IL-22 as major contributors in psoriasis pathogenesis. Advances in the knowledge of pathophysiology, the interaction of autoinflammation and clinical phenotypes have led to the development of highly effective targeted therapeutic agents which include TNF-α, IL-17, IL-23, IL-1α/β or IL-36 inhibitors or receptor blockers, small molecule drugs like phosphodiesterase-4 inhibitors (apremilast), Janus kinase (JAK) inhibitors, retinoic acid receptor-related orphan receptor γt (RORγt) inhibitors. These novel drugs have promised the potential of improved disease control. In recent years, the transition from biologics to biosimilars especially with TNF-α inhibitors had significant impact on decreasing health care cost and increasing therapeutic options to the patients. However, selection of right treatment for an individual patient still remains challenging. Moreover, interplay between different epigenetic mechanisms such as the DNA methylation, chromatin modifications and noncoding RNA regulation has recently been started to be deciphered. Enzymes inhibitors involved in epigenetic pathways such as DNA methyltransferases and histone deacetylases demonstrated to restore normal epigenetic patterns in clinical settings and have provided the potential as novel therapeutic targets for psoriasis. In this review, we will discuss novel biologic agents and newer therapeutic approaches in treatment of psoriatic disease.

INTRODUCTION

Psoriatic disease is a chronic relapsing inflammatory condition affecting ~2–3% of population (1, 2). Psoriatic disease consists of psoriasis vulgaris affecting skin and psoriatic arthritis affecting joints. Psoriasis affects patients’ quality of life significantly and have tremendous psychosocial burden among patients (3). The immunopathogenesis of psoriasis is complex primarily driven by an aberrant immune response further modified by an interplay between genetic susceptibility.
and environmental factors. The inflammatory events lead to systemic inflammation resulting in cardiovascular, metabolic and renal disease and increased morbidity (4). In last few years, advances in understanding molecular and cellular pathways have identified tumor necrosis factor-α (TNF-α), interleukin-17 (IL-17), IL-23, IL-22 as major contributors in psoriasis pathogenesis (5). This has led to the development of highly effective targeted therapeutic agents which include TNF-α, IL-17, IL-23, IL-1 α/β or IL-36 inhibitors or receptor blockers, small molecule drugs like phosphodiesterase-4 inhibitors (apremilast), Janus kinase (JAK) inhibitors, retinoic acid receptor-related orphan receptor-γT (RORyT) inhibitors (5). Figure 1 shows the pathogenesis and various therapeutic targets in psoriatic disease. These novel drugs have promised the potential of improved disease control. In this review, we will discuss novel therapeutic targets in the management of psoriatic disease.

**JAK INHIBITORS**

The Janus Kinase–Signal Transducer and Activator of Transcription (JAK–STAT) pathway plays an important role in intracellular signaling in various physiological and pathological processes in inflammatory disorders including psoriasis. Cytokines implicated in psoriasis pathogenesis mainly IL-17, IL-23, TNF-α, IL-1, IL-22, IFN-α and IFN-γ are linked to JAK-STAT pathway (6, 7). Upon interaction of various cytokines with their respective receptor, activation of JAK leads to phosphorylation of STAT proteins and nuclear translocation resulting in gene expression (8). In psoriasis, increased expression and upregulation of STAT1 and STAT3 have been demonstrated in the lesional skin (9, 10). STAT1 and STAT3 are involved in the activation of dendritic cells and differentiation of Th1 and Th17 cells (9, 10). STAT3 also leads to the keratinocyte proliferation mediated through IL-19, IL-36 and IL-22 (11). IFN-γ secreted from keratinocytes leads to the migration of inflammatory cells from the lymphoid tissue to the skin (10).

Various JAK inhibitors have been used in psoriatic disease with good efficacy, of which Tofacitinib, an oral JAK1/3 inhibitor, has been extensively studied in phase II and III trials (6). In phase III studies, a significant proportion of patients achieved PASI75 at weeks 12 or 16 showing greater efficacy with higher doses i.e., 10 mg twice daily (12). Studies evaluating the efficacy after treatment withdrawal also showed higher efficacy as compared to placebo (13). In another study, 74.1 and 79.4% of patients receiving tofacitinib 5 mg twice daily and 10 mg twice daily respectively, maintained the response at 52-weeks (14). Tofacitinib has shown significantly better efficacy and safety in psoriatic arthritis as compared to placebo (15, 16). A topical formulation of tofacitinib has also been developed and used in plaque psoriasis with modest efficacy (17). Common adverse effects include cytopenia and infections (6, 18). Safety concerns especially dose-dependent (i.e., 10 mg twice daily) risk of herpes zoster, higher chances of infections, gastric perforation and thromboembolic events has been raised (6, 18), although long-term studies with larger samples are needed. Due to these safety concerns, tofacitinib was not approved for psoriasis by FDA, however it is approved for use in psoriatic arthritis (6).

Baricitinib, an oral highly selective JAK1 and JAK2 inhibitor has also been studied in patients with moderate-to-severe psoriasis in Phase II trials and has shown better efficacy as compared to placebo at doses 8 mg and 10 mg (19). Adverse effects included anemia, cytophenia and increase in creatinine levels (6). Similar safety concerns have been raised with baricitinib, thus, it is approved for use in rheumatoid arthritis only.

Ruxolitinib, another JAK1 and JAK2 inhibitor, has been developed as topical cream and studies in psoriasis showed a better efficacy and safety profile compared to vehicle and Non-inferior to calcipotriol-betamethasone combination (17). Other JAK1/2 inhibitors such as itacitinib (20), abrocitinib (21), solcitinib (22) and filgotinib (23) have shown efficacy in phase II trials in psoriasis and psoriatic arthritis. Peficitinib, an oral pan-JAK inhibitor with JAK3 selectivity, showed a good efficacy in psoriasis in phase IIa trial with no major adverse events (24).

**IL-23**

IL-23, a cytokine of IL-12 family, consists of two subunits: p19 (unique for IL-23) and p40 that is common with IL-12 (25). IL-23 is mainly produce by dendritic cells and macrophages (26, 27). Initially, antibodies targeting p40 subunit of IL-12 were found effective in psoriasis as these neutralized IL-23 also (27). Later on, increased expression of p19 and p40 was found in psoriatic lesions while p35 that is specific to IL-12 was normal which suggested that IL-23 not IL-12 is an important cytokine involved in the psoriasis pathogenesis (28). IL-23 binds to its heterodimeric receptor leading to the activation of Janus kinases (Jak) and further activation of STAT3 (28). IL-23 leads to the production of cytokines from Th-17 cells i.e., IL-17, a major cytokine implicated in the pathogenesis of psoriasis (28). This led to development of anti-IL23 biologics in the therapeutics of psoriatic disease. As these agents target upstream cytokine involved in the psoriasis pathogenesis, dosing interval of longer duration is an advantage as compared to the downstream cytokines such as IL-17 and TNF-α (29). Currently, ustekinumab, guselkumab, tildrakizumab, and risankizumab are FDA approved for psoriasis vulgaris and only ustekinumab and guselkumab have been approved by the FDA for psoriatic arthritis (29). IL-23 inhibitors have shown superior efficacy to conventional agents and TNF-α inhibitors. A network metaanalysis found guselkumab and risankizumab more effective than tildrakizumab (30). The IL-23 inhibitors have been found to be more effective in maintaining remission as compared to other drugs even after drug discontinuation. In PHOENIX 1 trial of ustekinumab, median time to loss of PASI-50 was ~22 weeks from the last dose of drug (31). Similar results have been observed with other IL-23 inhibitors including guselkumab, tildrakizumab and risankizumab, showing sustained improvement in disease after drug discontinuation (32–34). The efficacy of IL-23 inhibitors especially ustekinumab and guselkumab in psoriatic arthritis was also found significantly high as compared to placebo.
However, more studies evaluating efficacy of these agents and comparison with other drugs such as TNF-α are required. Common adverse effects of IL-23 inhibitors include upper respiratory infections, nasopharyngitis, and headache (29). Other adverse events include serious infections, major adverse cardiovascular events and malignancy, however, the rates observed were comparable to seen in general population of psoriasis patients (29). A long-term data on the safety of these novel drugs is thus warranted.

**IL-36**

IL-36 (member of IL-1 family) binds to its receptor and leads to the activation of NF-κB and MAPKs pathways through MyD88/IRAK complex (38). Expression of IL-36γ have been found to be significantly upregulated in the serum and skin samples of psoriasis patients (39). Furthermore, loss of function mutation in IL-36Ra gene has been found in a severe variant of generalized pustular psoriasis (GPP) (40, 41). Studies in mouse model have observed psoriasis like epidermal changes, inflammatory cell infiltrate and gene dysregulation after IL-36 administration which was not seen when Pre-treatment with an IL-36 antagonist was administered (42). This supports a direct role of IL-36 in psoriasis pathogenesis and attenuating this signaling pathway may be an effective alternative approach to the already approved small molecules such as apremilast or other biologics. Moreover, studies have shown that individuals with loss of function mutation in IL-36Ra gene have normal immune function suggesting that targeting this cytokine may not lead to adverse events associated with immune dysregulation and may have a good safety profile (43). Recently, an oral small molecule inhibitor of IL-36, A-552 was shown to inhibit IL-36γ and production of other cytokines induced by IL-36γ in human and mouse cells (44). Monoclonal antibody against IL-36R, spesolimab has shown efficacy in a Phase I study, and phase II and III studies of spesolimab in GPP are currently undergoing (45, 46). Thus, anti-IL-36 agents may have a robust potential in therapeutics of psoriasis and further research evaluating their efficacy and safety is needed. Table 1 summarizes the studies of JAK inhibitors, IL-23 and IL-36 inhibitors in psoriasis and psoriatic arthritis.

**IL-1**

IL-1, a proinflammatory cytokine, comprise of IL-1α and IL-1β. Both these cytokines has been implicated in the pathogenesis of psoriasis (46). Increased expression of IL-1β has been found in the psoriatic skin and correlated with disease severity (47). Furthermore, IL-1β has been shown to induce Th17 cells and stimulate keratinocytes to secrete chemokines such as CCL20 (47). IL-1β production is also regulated by NLRP3 inflammasome as these inflammasomes cleave procaspases into caspases leading...
### TABLE 1 | Summary of various trials of JAK inhibitors, IL-23, IL-12/23 and IL-36 inhibitors.

| Drug          | Study/year | Setting/Dose | Number of patients | Response | Adverse effects | Conclusion | Phase |
|---------------|------------|--------------|--------------------|----------|-----------------|------------|-------|
| **JAK inhibitors** |            |              |                    |          |                 |            |       |
| Tofacitinib   | Papp et al. (87)/ 2012 | Psoriasis vulgaris–Tofacitinib 2 mg twice daily vs. 5 mg twice daily vs. 15 mg twice daily vs. placebo | Tofacitinib 2 mg–49; 5 mg–49; 15 mg–49; placebo–50 | At week 12, higher proportion of patients achieved PASI 75 in all tofacitinib groups: 25-0% (2 mg), 40-8% (5 mg) and 66-7% (15 mg) compared with placebo (2-0%). | Infections and infestations, | Oral tofacitinib results in significant clinical improvement in patients with moderate-to-severe plaque psoriasis. | Phase 2b |
|               | Bisonette et al. (13)/ 2015 | Moderate-to-severe plaque psoriasis–tofacitinib 5 mg or 10 mg twice daily for 24 weeks. The patients achieving both PASI75 and Physician’s Global Assessment of “clear” or “almost clear” received a placebo or the previous dose. At relapse (>50% reduction in the PASI improvement during initial treatment) or week 40, the patients received the initial dose. | Tofacitinib 5 mg–331; 10 mg–395 | 33-5% and 55-2% achieved both PASI 75 and PGA responses in tofacitinib 5 and 10 mg twice daily group, respectively. | Elevations in low-density lipoprotein–cholesterol levels | Patients who received continuous treatment maintained a response more effectively than placebo. Patients who relapsed, 60% reattained a response with tofacitinib. | Phase 3 |
|               | Bachelez et al. (88)/ 2015 | Moderate-to-severe plaque psoriasis–Tofacitinib 5 mg twice daily vs. 10 mg twice daily vs. Etanercept 50 mg twice weekly vs. placebo | Tofacitinib 5 mg–330; 10 mg–332; Etanercept: 336; placebo: 108 | At week 12, PASI75–39-5% in tofacitinib 5 mg group, 63-6% in tofacitinib 10 mg group, 58-8% in the etanercept group, and 5-6% in the placebo group. | Similar adverse events—2 in tofacitinib 5 mg group, 2% in tofacitinib 10 mg group, 2% in etanercept group, and 2% in placebo group. | Tofacitinib 10 mg twice daily was Non-inferior to etanercept and was superior to placebo, but 5 mg twice daily did not show Non-inferiority to etanercept. | Phase 3, randomized, multi-centre, placebo-controlled, 12-week, Non-inferiority trial. |
|               | Papp et al. (12)/ 2015 | Plaque psoriasis–tofacitinib 10 or 5 mg or placebo, twice daily. | Tofacitinib 5 mg–745; 10 mg–741; placebo–373 | At week 16, a greater proportion of patients achieved PGA responses with tofacitinib 5 and 10 mg twice daily vs. placebo. | Similar across groups. Twelve patients reported herpes zoster across the tofacitinib treatment groups. | Oral tofacitinib demonstrated significantly high efficacy as compared to placebo, during 16 weeks of treatment. | Phase 3 |
|               | Mease et al. (15)/ 2017 | Psoriatic arthritis–tofacitinib 5 mg twice daily, 10 mg twice daily, adalimumab 40 mg once every 2 weeks, placebo with a blinded switch to 5 mg tofacitinib at 3 months, or placebo with a blinded switch to 10 mg tofacitinib at 3 months. | Tofacitinib 5 mg–107; 10 mg–104; adalimumab: 106; placebo: 52 (5 mg switch), 53 (10 mg switch) | ACR20 response rates at month 3 were 50% in 5-mg tofacitinib group and 61% in 10-mg tofacitinib group, 33% in placebo group, 52% in the adalimumab group. | The rate of adverse events was 66% in 5-mg tofacitinib group, 71% in 10-mg tofacitinib group, 72% in adalimumab group. | Efficacy of tofacitinib was superior to placebo at month 3 in patients who previously had an inadequate response to conventional synthetic DMARDs. | 12-month, double-blind, active-controlled and placebo-controlled, phase 3 trial |

(Continued)
| Drug | Study/year | Setting/Dose | Number of patients | Response | Adverse effects | Conclusion | Phase |
|------|------------|--------------|--------------------|----------|----------------|------------|-------|
| Gladman et al. (16)/ 2017 | Psoriatic arthritis—tofacitinib 5 mg twice daily; 10 mg twice daily; placebo, with a switch to 5 mg tofacitinib twice daily at 3 months; or placebo, with a switch to 10 mg tofacitinib twice daily at 3 months. | Tofacitinib 5 mg—132; 10 mg—132; placebo-66 (5 mg switch), 65 (10 mg switch). | ACR20 response-50% with 5-mg tofacitinib and 47% with 10-mg dose, as compared to 24% with placebo. | 4 serious infections, 3 herpes zoster infections, 1 myocardial infarction, and 1 ischemic stroke. | Tofacitinib was more effective than placebo over 3 months in reducing disease activity. | 6-month randomized, placebo-controlled, double-blind, phase 3 trial |
| Papp et al. (19)/ 2016 | Moderate-to-severe psoriasis—placebo or oral baricitinib at 2, 4, 8 or 10 mg once daily for 12 weeks. | baricitinib 2 mg-32, 4 mg-72, 8 mg-64, 10 mg-69, Placebo-34 | At week 12, patients in 8-mg (43%) and 10- mg (54%) baricitinib groups achieved PASI-75 than in placebo group (17%). Statistically significant PASI-90 responses were achieved in 8-mg and 10-mg groups at 8 and 12 weeks. | treatment-emergent AE rates were 44, 50, 47, 58 and 64% for placebo and 2-, 4-, 8- and 10-mg baricitinib groups. | Treatment with baricitinib for 12 weeks achieved significant improvements in PASI-75. | Phase 2b, randomized, double-blind, placebo-controlled, dose-ranging study. |
| Phoenix-I (89)/ 2008 | Moderate-to-severe psoriasis—Ustekinumab 45 mg or 90 mg at weeks 0, 4 and then every 12 weeks; or placebo at weeks 0 and 4, with subsequent crossover to ustekinumab at week 12. | Placebo-255; 45 mg-255, 90 mg-256 | 67.1% patients receiving ustekinumab 45 mg, 66.4% receiving ustekinumab 90 mg, and 31.1% receiving placebo achieved PASI 75 at week 12. | Adverse events occurred in 54-5% in ustekinumab and 48.2% in placebo group. | Ustekinumab seems to be efficacious for the treatment of moderate-to-severe psoriasis; dosing every 12 weeks maintains efficacy for at least a year in most patients. | Phase 3, parallel, double-blind, placebo-controlled study. |
| Phoenix-II (90)/ 2008 | Moderate-to-severe psoriasis—Ustekinumab 45 mg or 90 mg at weeks 0, 4 and then every 12 weeks; or placebo. Partial responders (patients achieving ≥50% but <75% improvement from baseline in PASI) were re-randomized at week 28 to continue dosing every 12 weeks or escalate to dosing every 8 weeks. | Placebo-410; 45 mg-409, 90 mg—411 | 66.7% patients receiving ustekinumab 45 mg, 75.7% receiving ustekinumab 90 mg, and 37.7% receiving placebo achieved 75% improvement in PASI at week 12. More partial responders who received ustekinumab 90 mg every 8 weeks achieved PASI 75 at week 52 than those who received the same dose every 12 weeks. | Serious adverse events were seen in 2% patients in 45 mg group, 1.2% in 90 mg group, and 2% in placebo group. | Ustekinumab every 12 weeks is effective for most patients with moderate-to-severe psoriasis. Intensification of dosing to once every 8 weeks with ustekinumab 90 mg might be necessary to elicit a full response in patients who only partially respond to the initial regimen. | Multicentre, phase 3, double-blind, placebo-controlled study. |
| Griffiths et al. (91)/ 2010 | Moderate-to-severe psoriasis—45 or 90 mg of ustekinumab (at weeks 0 and 4) or high-dose etanercept (80 mg twice weekly for 12 weeks) | 45 mg—209; 90 mg—347; etanercept—347 | 75% improvement in the PASI at week 12 in 67.5% of patients receiving 45 mg of ustekinumab and 73.8% of patients receiving 90 mg, as compared with 56.8% of those with etanercept. | One or more adverse events occurred in 66% of patients in 45 mg ustekinumab and 69.2% in 90 mg ustekinumab and in 70% in etanercept group. | Efficacy of ustekinumab 45 or 90 mg was superior to high-dose etanercept over a 12-week period. | Randomized, multicentre study. |
| Drug                  | Study/year | Setting/Dose                                                                 | Number of patients | Response | Adverse effects | Conclusion | Phase          |
|-----------------------|------------|------------------------------------------------------------------------------|--------------------|----------|----------------|------------|----------------|
| **PSUMMIT I** (35)    |            | Active psoriatic arthritis—45 mg ustekinumab, 90 mg ustekinumab, or placebo at week 0, week 4, and every 12 weeks thereafter. | Placebo- 206; 45 mg- 205; 90 mg- 204 | More ustekinumab-treated [42.4%] in the 45 mg group and [49.5%] in the 90 mg group than placebo-treated [22.8%] patients achieved ACR20 at week 24. | Adverse events were similar in the ustekinumab [41.8%] and placebo groups [42.0%]. | Ustekinumab significantly improved active psoriatic arthritis. | Phase 3, multicentre, double-blind, placebo-controlled trial |
| **PSUMMIT II** (36)   |            | Active Psoriatic Arthritis—ustekinumab 45 mg or 90 mg at week 0, week 4, q12 weeks or placebo at week 0, week 4, week 16 and crossover to ustekinumab 45 mg at week 24, week 28 and week 40. | Placebo- 104; 45 mg- 103; 90 mg- 105 | More ustekinumab-treated (43.8% combined) than placebo-treated (20.2%) patients achieved ACR20 at week 24; all benefits were sustained through week 52. | No unexpected adverse events were observed. | Ustekinumab (45/90 mg q12 weeks) yielded significant and sustained improvements in Psoriatic Arthritis. | phase 3, multicentre, placebo-controlled trial |
| **IL-23 inhibitor**   |            | Gusekumab                                                                   | Placebo- 174; 100 mg- 329; adalimumab—334 | Gusekumab was superior to placebo at week 16 (73.3 vs. 2.9% [PASI-90]). Gusekumab was also superior to adalimumab for PASI 90 at week 16 (73.3 vs. 49.7%), week 24 (80.2 vs. 53.0%), and week 48 (76.3 vs. 47.9%). | The proportions of patients with adverse events were similar in the gusekumab and adalimumab group. | Gusekumab demonstrated superior efficacy compared with adalimumab. | phase 3, randomized, double-blind, placebo- and active comparator-controlled trial |
| **VOYAGE I** (92)     |            | Moderate to severe plaque psoriasis—gusekumab 100 mg (weeks 0 and 4, then every 8 weeks); placebo/gusekumab (weeks 0, 4, 12 and 16) gusekumab at weeks 16 and 20, then every 8 weeks; or adalimumab (80 mg week 0, 40 mg week 1, then 40 mg every 2 weeks through week 47). | Placebo- 248; 100 mg- 496; adalimumab—248 | Gusekumab was superior to adalimumab and placebo at week 16. From weeks 28 to 48, better persistence of response was observed in gusekumab maintenance vs. withdrawal groups. Of adalimumab Non-responders who switched to gusekumab, 66.1% achieved PASI 90 at week 48. | Adverse events were comparable among groups. | Gusekumab is highly effective maintenance therapy, including in adalimumab Non-responders. | phase 3, double-blind, placebo- and active comparator-controlled trial |
| **VOYAGE II** (93)    |            | Moderate to severe plaque psoriasis—Similar to VOYAGE I; at week 28, gusekumab PASI90 responders were rerandomized to gusekumab or placebo with gusekumab after loss of response. Placebo→ gusekumab responders and adalimumab responders received placebo, then gusekumab after loss of response. | Placebo- 248; 100 mg- 496; adalimumab—248 | Gusekumab was superior to adalimumab and placebo at week 16. From weeks 28 to 48, better persistence of response was observed in gusekumab maintenance vs. withdrawal groups. Of adalimumab Non-responders who switched to gusekumab, 66.1% achieved PASI 90 at week 48. | Adverse events were comparable among groups. | Gusekumab is highly effective maintenance therapy, including in adalimumab Non-responders. | phase 3, double-blind, placebo- and active comparator-controlled trial |
| **DISCOVER I** (37)   |            | Active psoriatic arthritis—100 mg every 4 weeks- 128; 100 mg at 0 and 4 weeks, then every 8 weeks- 127 | Placebo- 126; 100 mg every 4 weeks- 128; 100 mg at 0 and 4 weeks, then every 8 weeks- 127 | Significantly greater proportions of patients receiving gusekumab every 4-week (59.4%) and every 8-week (52.0%) vs. placebo (22.2%) achieved ACR20 at week 24. | Serious adverse events occurred in none of patients in gusekumab every 4-week, 3.1% in gusekumab every 8-week, and 4.0% in placebo group. | Gusekumab demonstrated a favorable benefit-risk profile and is an effective treatment option in patients with active psoriatic arthritis. | Phase-3, double-blind, placebo-controlled study |

(Continued)
| Drug                  | Study/year | Setting/Dose                                                                 | Number of patients | Response                                                                 | Adverse effects             | Conclusion                                                                 | Phase                        |
|----------------------|------------|------------------------------------------------------------------------------|--------------------|--------------------------------------------------------------------------|-----------------------------|----------------------------------------------------------------------------|-------------------------------|
| Tildrakizumab        | reSURFACE I (94) | Moderate-to-severe chronic plaque psoriasis - Tildrakizumab at weeks 0 and 4 during part 1 and at week 16 during part 2 (weeks 12 and 16 for participants re-randomized from placebo to tildrakizumab). | Placebo- 154 100 mg- 309 200 mg-308 Tildrakizumab-306 | At week 12, 62% in 200 mg group and 64% in 100 mg group achieved PASI 75, compared with 6% in placebo group. | Nasopharyngitis.            | Tildrakizumab 200 mg and 100 mg were efficacious compared with placebo.    | Parallel group, double-blind, randomized controlled study |
| Tildrakizumab        | reSURFACE II (94) | Moderate-to-severe chronic plaque psoriasis - Tildrakizumab at weeks 0 and 4 during part 1 and at week 16 during part 2 (weeks 12 and 16 for participants re-randomized from placebo to tildrakizumab; etanercept was given twice weekly in part 1 and once weekly during part 2). | Placebo- 156 100 mg- 307 200 mg-314 Etanercept-313 | At week 12, 66% in 200 mg group, and 61% in 100 mg group achieved PASI 75, compared with 6% in placebo group and 48% in the etanercept group. | The incidence of severe infections, malignancies, and major adverse cardiovascular events were low and similar across treatment groups. | Tildrakizumab 200 mg and 100 mg were efficacious compared with placebo and etanercept and were well tolerated. | Parallel group, double-blind, randomized controlled study |
| Risankizumab         | UltIMMa-1 and UltIMMa-2 (95) | Moderate-to-severe chronic plaque psoriasis—150 mg risankizumab, 45 mg or 90 mg ustekinumab or placebo. Following 16-week double-blind treatment period (part A), patients initially assigned to placebo switched to 150 mg risankizumab at week 16; other patients continued their originally randomized treatment (part B, double-blind, weeks 16–52). Study drug was administered subcutaneously at weeks 0 and 4 during part A and at weeks 16, 28, and 40 during part B. | UltIMMa-1 - Placebo- 102; 150 mg-304; ustekinumab-100 UltIMMa-2 - Placebo-98; 150 mg-294; Ustekinumab- 99 | At week 16 of UltIMMa-1, PASI 90 was achieved by 75.3% patients receiving risankizumab vs. 4.9% receiving placebo and 42.0% receiving ustekinumab. At week 16 of UltIMMa-2, PASI 90 was achieved by 74.8% patients receiving risankizumab vs. 2.0% receiving placebo and 47.5%. | The frequency of treatment-emergent adverse events in UltIMMa-1 and UltIMMa-2 was similar across risankizumab, placebo, ustekinumab, and placebo to risankizumab groups. | Risankizumab showed superior efficacy to both placebo and ustekinumab. | Phase 3, randomized, double-blind, placebo-controlled and active comparator-controlled trials |
| IL-36 inhibitor      | Bachelé et al. (96) | Generalized Pustular Psoriasis—single 900-mg intravenous dose of spesolimab or placebo. Patients in both groups received an open-label dose of spesolimab on day 8, an open-label dose of spesolimab as a rescue medication after day 8, or both and were followed to week 12. | Spesolimab 900 mg- 35; placebo-18 | At week 1, 54% in the spesolimab group had a pustulation sub-score of 0, as compared with 6% in the placebo group. | Drug reactions—2 patients. (drug-induced hepatic injury-1); infections—17% through the first week; antidrug antibodies—46%. | Spesolimab resulted in a higher incidence of lesion clearance at 1 week than placebo but was associated with infections and systemic drug reactions. | Phase 2 randomized trial |
to the production of IL-1β (48). Higher caspase-1 and IL-1β levels has been observed in patients with psoriasis that normalized after treatment with TNF-α (48). Anti-IL1 agents such as anakinra, canakinumab and gevokizumab have shown efficacy in psoriasis. Anakinra, a recombinant IL-1 receptor antagonist (IL-1Ra) inhibits both IL-1α and IL-β and has shown efficacy in pustular psoriasis and deficiency of IL-1 receptor antagonist (DIRA) variant (49). However, the partial responses observed suggest role of other cytokines of IL-1 family such as IL-36 (49, 50). Canakinumab, an anti-IL-β antibody has also shown beneficial effects in GPP (51). Gevokizumab, another novel IL-1β antagonist has shown its efficacy in GPP (52). In 2 patients of GPP, 79 and 65% improvement in GPP scores was observed after 4 weeks (52). Thus, IL-1 inhibitors particularly IL-1β could be potentially efficacious in management of psoriasis especially pustular psoriasis, though larger studies are needed.

**RORγT ANTAGONISTS**

RORγT is an important transcription factor required for the differentiation of Th17 cells and regulates the expression of Th17 cytokines i.e., IL-17A, IL-17F, IL-22 and IL-23 receptor (53). Thus, RORγT inhibition seems to be an effective strategy in therapeutics of psoriasis. VTP-43742, an oral RORγT inhibitor is undergoing phase III study in treatment of plaque psoriasis. In a phase IIa study, 29 and 23% reduction in PASI was observed at 4 weeks in patients receiving 700 mg and 350 mg of VTP-43742 respectively along with 75% reduction in IL-17A and IL-17F levels in both groups (54). Side effects included headache, flushing, elevated liver enzymes and nausea. Other agents such as JTE-451 and ABBV-157, oral RORγT inhibitors are currently in phase 2 and phase 1 of development respectively, for the treatment of moderate to severe psoriasis. New systemic and topical RORγT inhibitors may be the potential candidates for the treatment of psoriasis (55).

**TYK2 INHIBITORS**

The TYK2, a JAK family gene, has been associated with psoriasis susceptibility genes and loss of function mutation is associated with various cytokine signaling defects that are implicated in psoriasis pathogenesis (56, 57). Individuals with these mutations have been found to be unaffected by immune-mediated inflammatory diseases without being susceptible to life-threatening infections (58). These observations suggested that TYK2 inhibitors may be a safe therapeutic target. BMS-986165 is an oral highly selective TYK2 inhibitor and inhibit STAT1 and STAT3 phosphorylation in peripheral blood mononuclear cells stimulated with IFN-α and IL-23 (6). BMS-986165 has shown good efficacy in psoriasis in phase II trials at doses 3 mg, 6 mg and 12 mg daily (59). Common adverse effects include headache, nausea, diarrhea, and upper respiratory tract infections (59). Phase III trials in plaque psoriasis and phase II trial in psoriatic arthritis are currently ongoing (6). Another selective TYK2 inhibitor, PF-06826647, is also being tested in moderate-to-severe psoriasis in an ongoing phase II clinical trial (NCT03895372) (6). Brexocitinib (formerly known as PF-06700841) is not a selective TYK2 inhibitor (rather a potent TYK2/JAK1 inhibitor), has shown good efficacy in phase II trials in psoriasis with few minor adverse effects, except thrombocytopenia and decreased reticulocyte count (60). A phase Ib study is currently undergoing to evaluate the efficacy and safety in psoriatic arthritis (6). A topical formulation is also being tested in mild to moderate psoriasis. These small molecules have advantages like oral route of administration, decreased cost, less immunologic adverse events as compared to biologics.

**SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 (S1PR1) ANTAGONIST**

Sphingosine-1-phosphate (S1P) is involved in cell proliferation and survival, migration, inflammation and angiogenesis (61, 62). S1P inhibits the keratinocyte proliferations and increase cell differentiation (63). Ponesimod, an oral S1P receptor 1 antagonist leads to the downregulation of S1P receptor and prevent migration of lymphocytes from lymph nodes to skin in psoriasis (64). In a phase 2 study, PASI75 was achieved in 46 and 48% of patients receiving ponesimod 20 mg and 40 mg respectively as compared to placebo at 16-weeks and the improvement continued till 28 weeks (65). However, effect is not maintained after drug discontinuation due to its rapid elimination within 1 week. Adverse effects include transaminitis, shortness of breath, dizziness and may cause conduction abnormalities, thus contraindicated in patients with cardiac disease (65).

**A3 ADENOSINE RECEPTOR AGONIST**

A3 adenosine receptors are G-protein coupled receptors involved in various intracellular pathways. These receptors have been found to be highly expressed on peripheral mononuclear cells in psoriasis patients (66). Pidolenoson, an oral A3 adenosine receptor agonist has been found to downregulate NF-κB signaling pathway and pro-inflammatory cytokines such as TNF-α, IL-6 and IL-12, and inhibit T-lymphocyte proliferation (67). In a phase II trial, a significant reduction in PASI was observed at 12 weeks as compared to placebo and drug was well tolerated (67). Currently, the drug is in phase III trials.

**mTOR INHIBITORS**

The PI3-K/Akt/mTORC1 cascade acts as a regulator of epidermal homeostasis (68). Akt has been shown to be highly activated in skin of psoriatic lesions, except in the basal layer and mTOR, expression is found to be increased in lesional and Non-lesional skin of psoriasis patients (69, 70). An animal model study showed that the PUVA treatment led to improvement in psoriasis and normalization of mTORC1 signaling (71). This suggested a pathophysiological role of mTORC1 signaling in psoriasis. The increased expression of mTORC1 may have a role in increased proliferation of keratinocytes and decreased differentiation. During normal
keratinization, mTORC1 signaling pathway is inactivated as the keratinocyte differentiation occurs (72). mTORC1 signaling also plays important roles in the innate and adaptive immunity (72, 73). Aberrant mTORC1 signaling was found in peripheral blood mononuclear cells (PBMCs) of psoriasis patients (74). Rapamycin, a mTOR inhibitor, has been used in few patients with psoriasis due to its antiproliferative and immunosuppressive actions (75). Everolimus was also used successfully in a psoriasis patient along with tacrolimus (76). Topical rapamycin has also been used in psoriasis showing clinical improvement (77). Thus, oral and topical mTOR inhibitors may be a successful therapeutic strategy in psoriasis and further research exploring the role of mTOR pathway as therapeutic target is warranted.

**FUTURE PERSPECTIVE**

Recent advances in understanding the pathogenesis of the psoriasis has led to the development of newer therapies such as biologics and other small molecules. However, apart from the therapeutic options discussed, various other cells and pathways are implicated in the pathogenesis such as role of natural killer cells, regulatory T-cells and mesenchymal stem cells (MSCs). The regulatory T-cells have been found increased in lesional skin of psoriasis patients. Similarly, IL-10-producing regulatory B cells of psoriasis patients were reduced in number and showed decreased IL-10 production. MSCs have been implicated in the psoriasis pathogenesis and may serve as potential therapeutic target. MSCs have immunomodulatory properties and affect Th1 and Th17 lymphocytic inhibition in psoriatic skin (78). These MSCs have also been found to have pleiotropic effects of biologic therapy in psoriasis (79). MSCs based therapy has been tried in few patients with psoriasis with successful outcomes (80–82). However, larger studies are still needed to fully explore the role of these cells as a therapeutic option. Another class of drug i.e., selective serotonin reuptake inhibitors (SSRIs) have been found to be beneficial in psoriasis due to their anti-inflammatory properties and reduction in cytokine levels (83). Moreover, these agents prevent T-cell proliferation by reduced antigen presentation by dendritic cells and causes inflammatory cell apoptosis (83). Role of proanthocyanidins having antioxidant, anti-proliferative, antiangiogenic and anti-inflammatory properties as an therapeutic option needs to be investigated as oxidative stress plays an important role in the pathogenesis of psoriasis (84). A potent and selective NF-κB inducing kinase (NIK) inhibitor has been found effective in imiquimod induced psoriasis in animal model, highlighting the potential of newer strategy for the treatment of psoriasis (85). Mutations in CARD14 have been found in psoriasis patients (86). Such genetic associations indicate a role in immune regulatory pathways involved in psoriasis. Such observations may help in the better knowledge of psoriasis susceptibility genes and individualized approaches in management of psoriasis. In addition, the role of keratinocytes as initiators of psoriatic inflammation might further shift the focus to topical treatments. Further studies are needed to obtain better insights in the immunopathogenesis of the disease that may lead to the development of more targeted and effective therapies.

**CONCLUSION**

Many novel systemic and topical therapies are currently in development. The success of these agents depends on the efficacy and safety of these drugs in future studies. Better understanding of inflammatory pathways involved the pathogenesis and newer discoveries may lead to the effective therapeutic strategies in management of psoriasis.

**AUTHOR CONTRIBUTIONS**

VT: study design, acquisition, analysis or interpretation of data, and drafting of the manuscript. RM: study concept and design, acquisition, analysis or interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content, statistical analysis, administrative, technical, or material support, and study supervision. All authors contributed to the article and approved the submitted version.

**REFERENCES**

1. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. (2017) 31:205–12. doi: 10.1111/jdv.13854
2. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. Jama. (2020) 323:1945–60. doi: 10.1001/jama.2020.4006
3. Augustin M, Radtke MA. Quality of life in psoriasis patients. Expert Rev Pharmacoecon Outcomes Res. (2014) 14:559–68. doi: 10.1586/14737167.2014.914437
4. Davidovici BB, Sattar N, Prinz J, Puig L, Emery P, Barker JN, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. (2010) 130:1785–96. doi: 10.1038/jid.2010.103
5. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. (2017) 140:645–53. doi: 10.1016/j.jaci.2017.07.004
6. Nogueira M, Puig L, Torres T. JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors. Drugs. (2020) 80:341–52. doi: 10.1007/s40265-020-01261-8
7. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. (2009) 129:1339–50. doi: 10.1038/jid.2009.59
8. Harrison DA. The Jak/STAT pathway. Cold Spring Harb Perspect Biol. (2012) 4:a011205. doi: 10.1101/cshperspect.a011205
9. Hald A, Andrés RM, Salskov-Iversen ML, Kjellerup RB, Iversen L, Johansen C. STAT1 expression and activation is increased in lesional psoriatic skin. Br J Dermatol. (2013) 168:302–10. doi: 10.1111/bjd.12949
10. Calautti E, Avalle L, Poli V. Psoriasis: a STAT3-Centric view. Int J Mol Sci. (2018) 19:171. doi: 10.3390/ijms19010171
11. Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, Kiguchi K, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med. (2005) 11:43–9. doi: 10.1038/nm1162
25. Oppmann B, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. (2015) 173:949–61. doi: 10.1111/bjd.14018

26. Bissoune R, Iversen L, Sofen H, Griffiths CE, Foley P, Romiti R, et al. Tofacitinib withdrawal and retreatment in moderate to severe chronic plaque psoriasis: a randomized controlled trial. Br J Dermatol. (2015) 172:1395–406. doi: 10.1111/bjd.13551

27. Yawalkar N, Tscharner GG, Hunger RE, Hassan AS. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. J Clin Investig. (2009) 119:1595–606. doi: 10.1172/JCI35910

28. Pastor-Fernandez G, Mariblanca IR, Navarro MN. Decoding IL-23 signaling cascade for new therapeutic opportunities. Cells. (2020) 9:204. doi: 10.3390/cells9022044

29. Yang K, Oak ASW, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. (2021) 22:173–92. doi: 10.1007/s40257-020-00578-0

30. Sawyer LM, Malottki K, Sabry-Grant C, Yasmeen N, Wright E, Sohrt A, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PAsI response. PLoS One. (2019) 14:0220868. doi: 10.1371/journal.pone.0220868

31. Kimball AB, Gordon KB, Fakhrazadeh S, Yelidding N, Szapory PO, Schenkel B, et al. Long-term efficacy of ustekinumab in patients with moderate to severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. (2012) 166:861–72. doi: 10.1111/j.1365-2133.2012.10901.x

32. Malyar K, O’Toole A, Gooderham MJ. Long-term single center experience in treating plaque psoriasis with guselkumab. J Cutan Med Surg. (2020) 24:588–95. doi: 10.1177/120347420932514

33. Warren RB, Carrascosa JM, Fumero E, Schoenenger B, Lebwohl MG, Szepietowski JC, et al. Time to relapse after tildrakizumab withdrawal in patients with moderate to severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial. J Eur Acad Dermatol Venereol. (2021) 35:919–27. doi: 10.1111/jdv.16964

34. Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, et al. Efficacy and safety of continuous risankizumab therapy vs. treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. (2020) 156:649–58. doi: 10.1001/jamadermatol.2020.0723

35. McNees IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. (2013) 382:780–9. doi: 10.1016/S0140-6736(13)60594-2

36. Ritchlin C, Rahman P, Kavanaugh A, McNees IB, Puig L, Li S, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. (2014) 73:990–9. doi: 10.1136/annrheumdis-2013-204655

37. Deodhar A, Hellisell PS, Boehncke WH, Kollmeier AP, Hisa EC, Subramanian RA, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitors treatment. (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. (2020) 395:1115–25. doi: 10.1016/S0140-6736(20)30265-8

38. Madonna S, Girolomoni G, Dinarello CA, Albanesi C. The Significance of IL-36γ mutations validates IL-36 as a psoriasis therapeutic target. An analysis of IL-36 signature genes and individuals with IL1RL2 knockout generalized pustular psoriasis. J Invest Dermatol. (2015) 135:1067–76. doi: 10.1038/jid.2014.318

39. D’Erme AM, Wilsmann-Theis D, Wagenpfeil J, Hölzel M, Ferring-Schmitt S, Sternberg S, et al. IL-36 (IL-1F9) is a biomarker for psoriasis skin lesions. J Invest Dermatol. (2015) 135:1025–32. doi: 10.1038/jid.2014.532

40. Johnston A, Xing X, Wolerink L, Barnes DH, Yin Z, Reingold L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. (2017) 140:109–20. doi: 10.1016/j.jaci.2016.08.056

41. Hussain S, Berki DM, Choon SE, Burden AD, Allen MH, Arostegui JJ, et al. IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. J Allergy Clin Immunol. (2015) 135:1067–70.e9. doi: 10.1016/j.jaci.2014.09.043

42. Su Z, Paulsboe S, Wetter J, Salte K, Kannan A, Mathew S, et al. IL-36 receptor antagonistic antibodies inhibit inflammatory responses in preclinical models of psoriasisform dermatitis. Exp Dermatol. (2019) 28:113–20. doi: 10.1111/exd.13841

43. Mahil SK, Catapano M, Di Meglio P, Dand N, Ahlfors H, Carr IM, et al. Small molecule IL-36γ Antagonist as a novel therapeutic approach for plaque psoriasis. Sci Rep. (2019) 9:9089. doi: 10.1038/s41598-019-4562-w
45. Ratnarajah K, Ifti A, Litvinov IV, Netchiporouk E. Sposolimab: a novel treatment for pustular psoriasis. J Cutan Med Surg. (2020) 24:199–200. doi: 10.1177/1023475419888862
46. Izanido H, Puig L. The interleukin-1 family cytokines in psoriasis: pathogenic role and therapeutic perspectives. Expert Rev Clin Immunol. (2021) 17:187–99. doi: 10.1080/14766891.2021.1886081
47. Cai Y, Xue F, Quan C, Qiu M, Liu N, Zhang Y, et al. A critical role of the IL-1β-IL-1R Signaling Pathway in Skin Inflammation and Psoriasis Pathogenesis. J Invest Dermatol. (2019) 139:146–56. doi: 10.1016/j.jid.2018.07.025
48. Verma D, Fekri SZ, Sigurdardottir G, Bivik Eding C, Sandin C, Enerbäck C. Enhanced inflammasome activity in patients with psoriasis promotes systemic inflammation. J Invest Dermatol. (2021) 141:586–95.e5. doi: 10.1016/j.jid.2020.07.012
49. Tauber M, Viguier M, Alimova E, Petit A, Lioté F, Smahi A, et al. Partial clinical response to anakinra in severe palmoplantar pustulosis. Br J Dermatol. (2014) 171:664–9. doi: 10.1111/bjd.13012
50. Wang WM, Jin HZ. Biologics in the treatment of pustular psoriasis. Expert Opin Drug Saf. (2020) 19:969–80. doi: 10.1080/14740338.2020.1785427
51. Skendros P, Papagoras C, Lefaki I, Giatriomanolaki A, Kotsianidis I, Spletas M, et al. Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition. Br J Dermatol. (2017) 176:212–5. doi: 10.1111/bjd.14685
52. Mansouri B, Richards L, Menter A. Treatment of two patients with generalized pustular psoriasis with the interleukin-1β inhibitor gevokizumab. Br J Dermatol. (2015) 173:239–41. doi: 10.1111/bjd.13614
53. Tang L, Yang X, Liang Y, Xie H, Dai Z, Zheng G. Transcription factor retinoid-related orphan receptor-γ: a promising target for the treatment of psoriasis. Front Immunol. (2018) 9:1210. doi: 10.3389/fimmu.2018.01210
54. Pandya VB, Kumar S, Sachchidanand, Sharma R, Desai RC. Combating autoimmune diseases with retinoic acid receptor-related orphan receptor-γ (ROγR or ROcR) Inhibitors: Hints and Misses. J Med Chem. (2018) 61:10976–95. doi: 10.1021/acs.jmedchem.8b00588
55. Imura C, Ueyama A, Sasaki Y, Shimizu M, Funae Y, Tai N, et al. A novel ROγt inhibitor is a potential therapeutic agent for the topical treatment of psoriasis with low risk of thymic aberrations. J Dermatol Sci. (2019) 93:176–85. doi: 10.1016/j.jdermsci.2019.03.002
56. Strange A, Capon F, Spencer CC, Knight J, Weale ME, Allen MH, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet. (2010) 42:985–90. doi: 10.1038/ng.694
57. Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K, Tsuchiya S, et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity. (2006) 25:745–55. doi: 10.1016/j.immuni.2006.09.008
58. Demouza CA, Cortes A, Shipman L, Evans HG, Attfield KE, Jostins L, et al. Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. J Exp Med. (2016) 16:8363ra149. doi: 10.1126/scitranslmed.aag1974
59. Papp K, Gordon K, Thaić D, Morita A, Gooderham M, Foley P, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. (2018) 379:1313–21. doi: 10.1056/NEJMoa1806382
60. Forman S, Pariser D, Poulin Y, Vincent M, Gilbert S, Kieras E, et al. editors. A Phase 2A, randomised, double-blind, placebo-controlled study to evaluate efficacy and safety of PF-06700841 in patients with moderate-to-severe plaque psoriasis. Experimental Dermatology. (2018) 38:1031–2. doi: 10.1111/exd.13482
61. Chimenti S, Arenberger P, Holló P, Sator PG, Burcklen M, Vaclavkova A, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet. (2010) 42:985–90. doi: 10.1038/ng.694
62. Vallotton R, Mörschel C, Künzle C, Fleischer AB, Goldmann T, Götz F, et al. Treatment of psoriasis vulgaris and psoriatic arthritis: a case report. J Cell Immunol. (2019) 258:115–22. doi: 10.1016/j.cellimm.2009.03.020
63. Reitamo S, Spuls P, Sosasol B, Lahte M, Claudey A, Griffiths CE. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol. (2001) 145:438–45. doi: 10.1046/j.1365-2133.2001.04376.x
64. Wei KC, Lai PC. Combination of everolimus and tacrolimus: a potentially effective regimen for recalcitrant psoriasis. Dermatol Ther. (2015) 28:25–7. doi: 10.1111/dth.12176
65. Ormerod AD, Shah SA, Copeland P, Omar G, Winfield A. Treatment of pustular psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial. Br J Dermatol. (2005) 152:758–64. doi: 10.1111/j.1365-2133.2005.06438.x
66. Paganelli A, Tarentini E, Benassi L, Kaleci S, Magnoni C. Mesenchymal stem cells for the treatment of psoriasis: a comprehensive review. Clin Exp Dermatol. (2020) 45:824–30. doi: 10.1111/ced.14269
67. Campanati A, Orciani M, Corbi S, Regoli F, Di Primio R, Offidani A. Effect of biologic therapies targeting tumour necrosis factor-α on cutaneous mesenchymal stem cells in patients with psoriasis. Br J Dermatol. (2012) 167:68–76. doi: 10.1111/j.1365-2133.2012.10900.x
68. Chen H, Niu JW, Ning HM, Pan X, Li Y, et al. Treatment of psoriasis with mesenchymal stem cells. Am J Med. (2016) 129:e13–4. doi: 10.1016/j.amjmed.2015.11.001
69. De Jesus MM, Santiago JS, Trinidad CV, See ME, Semon KR, Fernandez MO Jr, et al. Autologous adipose-derived mesenchymal stromal cells for the treatment of psoriasis vulgaris and psoriatic arthritis: a case report. Cell Transplant. (2016) 25:2063–9. doi: 10.3727/096369616X691998
70. Seetharaman R, Mahmood A, Kshatriya P, Patel D, Srivastava A. Mesenchymal stem cell conditioned media ameliorates psoriasis vulgaris: a case study. Cell Rep Dermatol Med. (2019) 2019:8309103. doi: 10.1155/2019/8309103
71. Martins AM, Ascenso A, Ribeiro HM, Marto J. Current and future therapies for psoriasis with a focus on serotonergic drugs. Mol Neurobiol. (2020) 57:2391–49. doi: 10.1007/s12035-020-01889-3
84. Lai R, Xian D, Xiong X, Yang L, Song J, Zhong J. Proanthocyanidins: novel treatment for psoriasis that reduces oxidative stress and modulates Th17 and Treg cells. Redox Rep. (2018) 23:130–5. doi: 10.1080/13510002.2018.1462027

85. Zhu Y, Ma Y, Zu W, Song J, Wang H, Zhong Y, et al. Identification of N-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as novel, potent, and selective NF-κB Inducing Kinase (NIK) inhibitors for the treatment of psoriasis. J Med Chem. (2020) 63:6748–73. doi: 10.1021/acs.jmedchem.0c00055

86. Sugiuira K. The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants. J Dermatol Sci. (2014) 74:187–92. doi: 10.1016/j.jdermsci.2014.02.006

87. Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. (2012) 167:668–77. doi: 10.1111/j.1365-2133.2012.11168.x

88. Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. (2015) 386:552–61. doi: 10.1016/S0140-6736(14)62113-9

89. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. (2008) 371:1665–74. doi: 10.1016/S0140-6736(08)60725-4

90. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. (2008) 371:1675–84. doi: 10.1016/S0140-6736(08)60726-6

91. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. (2010) 362:118–28. doi: 10.1056/NEJMoa1010652

92. Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. (2017) 76:405–17. doi: 10.1016/j.jaad.2016.11.041

93. Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. (2017) 76:418–31. doi: 10.1016/j.jaad.2016.11.042

94. Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. (2017) 390:276–88. doi: 10.1016/S0140-6736(17)31279-5

95. Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. (2018) 392:650–61. doi: 10.1016/S0140-6736(18)31713-6

96. Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. (2021) 385:2431–40. doi: 10.1056/NEJMoa2111563

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Thakur and Mahajan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.